The United States Centers for Disease Control and Prevention (CDC) issued an alert to healthcare providers on Tuesday (25) about an increased risk of dengue virus infections in the country.
Cases of the mosquito-borne viral disease have reached a record high in the Americas this year, the agency said, echoing a similar statement from the World Health Organization last month.
The number of dengue cases reported in the Americas exceeded 9.7 million during the period between January 1 and June 24, twice as many as in all of 2023, the CDC said, adding that a higher-than-expected volume of cases had been identified among travelers from the United States.
The agency urged healthcare providers to take measures such as promoting preventive actions, appropriate diagnostic tests and timely reporting of dengue cases to public health authorities, among other things, to contain the spread of the infection.
Last month, the WHO “prequalified” Takeda Pharmaceuticals’ Qdenga dengue vaccine, making it eligible for procurement by UN agencies such as Unicef and the Pan American Health Organization.
Qdenga is approved in the European Union, Indonesia, Thailand, Argentina and Brazil, among other places.
Dengvaxia from French pharmaceutical company Sanofi is also approved in several countries in the Americas, Europe and Asia.
Source: CNN Brasil
Bruce Belcher is a seasoned author with over 5 years of experience in world news. He writes for online news websites and provides in-depth analysis on the world stock market. Bruce is known for his insightful perspectives and commitment to keeping the public informed.
